Rimegepant

FDA APPROVAL DATE: 02/27/2020

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Fluconazole, Itraconazole, Rifampin, strong CYP3A4 inhibitors; moderate CYP3A4 inhibitors; strong and moderate CYP3A inducers; inhibitors of P-gp or BCRP


No adequate data on the developmental risk associated with use in pregnant women.

Our database has 6 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
RESPIRATORY.


Page last updated 09/03/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top